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Biobanks are collections of donations of biological material (DNA, cells, tissue
etc.) and related data which are very valuable for research into human
diseases. A variety of biobanks exist for example within hospitals, research
institutes, pharmaceutical companies and patient organisations. The role of
patients in biobanking is changing from being seen simply as donors, to
actual collaborators in the design, development and the running of biobanks.
In this article, we provide a number of examples of patients acting as partners
at the heart of biobanking, where their voice and perspective is being seen
and used as a valuable resource for the biobank. Our aim is that these
examples can be used by those who work with patients in biobank-based
research, to design future strategies for patient and public involvement in all
biobanks.
Abstract
Biobanks and biobanking research plays an increasingly important role in
healthcare research and delivery as health systems become more patient-
centred and medicine becomes more personalised. There is also growing ac-
ceptance and appreciation of the value that patients, patient advocacy organi-
sations and the public can bring as stakeholders in biobanking and more
generally in research. Therefore, the importance of active, early and sustained
engagement and involvement of patient and public representatives in biobanks
will become increasingly relevant.
Organising and facilitating patient and public involvement in biobanking takes
considerable time and effort for all stakeholders involved. Therefore, for any
biobank operator considering involving patients and the public in their
biobanking activities, consideration of best practices, current guidance, ethical
issues and evaluation of involvement will be important.
In this article, we demonstrate that patients are much more than donors to
biobanks—they are collaborators at the heart of biobanking with an important
voice to identify perspective, which can be an extremely valuable resource for
all biobanks to utilise. The case studies herein provide examples of good
practice of patient involvement in biobanking as well as outcomes from these
practices, and lessons learned. Our aim is to provide useful insights from these
efforts and potential future strategies for the multiple stakeholders that work
with patients and the public involved in biobank-based research.
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Biobanks collect, process, store and distribute biological material and related data to re-
search organisations. These “biospecimens” and data are used by scientists to learn
more about human diseases, their causes and their effects and to develop better pre-
vention measures, better diagnostic tests and better therapies [1]. Different types of
biobanks exist and are described in greater detail in the “Definitions” section below.
Unless otherwise stated, the term “biobank” in this article refers to disease-oriented,
general biobanks comprising of human tissue, cell or DNA biosamples and associated
clinical data (see “Definitions” section).
Biobanks do not operate in isolation. They exist within a diverse “ecosystem”
of stakeholders which includes the public, patients, healthcare workers, scientists,
government, funders, healthcare providers, ethicists, regulators and others. The
sheer variety of stakeholders involved in maintaining biobanks reflects the diver-
sity of biobanks themselves [2]. Biobanking operators such as hospitals, research
institutes, pharmaceutical companies and patient organisations interpret their
own biobanking activities differently, very often according to the background
of the founding organisation and the particular context in which the biobank is
embedded (e.g. geographical location, ability to network nationally or inter-
nationally etc.).
The role of patients and the public in biobanking activities has been viewed tradition-
ally as biobank participants rather than as collaborators in the design, development and
ongoing operation and governance of biobanks. However, there is growing acceptance
and appreciation of the value that patients, patient advocacy organisations and the
public can bring as stakeholders in biobanking and more generally in research [3, 4].
This article demonstrates the wealth of experience that now exists within patient
communities which makes them valuable partners and sources of input in biobank-
ing research. We demonstrate that patients are much more than donors—they are
collaborators at the heart of biobanking with an important voice and a unique per-
spective, which can be an extremely valuable resource for all biobanks to utilise. The
case studies herein provide examples of good practice of patient involvement in bio-
banking as well as outcomes from these practices, and lessons learned. Our aim is to
provide useful insights from these efforts and potential future strategies for the mul-
tiple stakeholders that work with patients and the public involved in biobank-based
research.
Definitions
The term “patient” in this article refers to the patient, his/her relatives or patient advo-
cates as collaborative or representative voice of patients.
The term “patient involvement” in this article refers to “involvement in research” (i.e.
being actively involved in the research process itself, rather than being participants or
subjects of the research).
The term “patient organisation” in this article refers to not-for-profit organisations
which are patient focused, and whereby patients and/or carers (the latter when patients
are unable to represent themselves) represent a majority of members in governing bod-
ies. These could be either general umbrella organisations (e.g. representing either spe-
cific disease organisations and/or national umbrella organisations) or disease-specific
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and/or chronic diseases).
The term “biobank” generally refers to a service whereby biological materials
and the data associated with those materials are collected, stored, processed
and distributed for the purposes of scientific research and/or medical treatment.
Typically, those “biological materials” are human samples—such as tissue, blood,
body fluids etc., and the “data” is any information, including medical information
pertaining to the donor of that sample. Biobanks exist within a variety of
institutions, including academic medical institutions, and pharmaceutical and bio-
technology companies. They can also be stand-alone organisations, including inde-
pendent companies (both for profit and non-profit) that can provide biobanking
services and access to samples as a service to the research community or patients.
There are multiple designs according to different possible goals. Briefly, human
sample-related biobanks include three major types: Population biobanks: whose primary goal is to obtain biomarkers of population
identity and susceptibility, typically from the DNA of large numbers of healthy
donors, representative of a country/region/ethnic cohort.
 Disease-oriented biobanks for epidemiology: whose activity is focused on
biomarkers of exposure, using large numbers of samples, usually following a
healthy exposed cohort/case-control design, and studying germ-line DNA or
serum markers and large amounts of specifically designed and collected
data.
 Disease-oriented general biobanks (e.g. tumour banks): where their goals
correspond to biomarkers of disease through collections of biosamples and their
derivates (DNA/RNA/proteins), usually associated to clinical data and sometimes
associated to clinical trials. The amount of clinical data linked to the sample
determinate the availability and biological value of the sample.
Unless otherwise stated, the term “biobank” in this article refers to disease-oriented
general biobanks, comprising of human tissue, cell or DNA biosamples and associated
clinical data.Main theories and background
Towards a patient-centred approach to healthcare—role of biobanking
Directly involving patients and the public in shaping both the organisation and delivery
of healthcare services is central to current health reform agendas around the world.
Realigning public services based on evidence from service user’s experiences, and de-
signed with and by the public rather than on their behalf, is challenging national
healthcare systems, with particular examples emerging in the USA and UK [5, 6]. It is
becoming clear that different types of involvement exist and approaches to involvement
are different in those countries that adopt either a “rights-based” or a “regulatory” ap-
proach to healthcare [7].
Developing in parallel to patient-centred healthcare is the concept of personalised
medicine [8]. In order to serve the needs of personalised medicine, biobanks and
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delivery. It is predicted that the integration of biobanking at all levels of disease-specific,
epidemiological and applied biomedical research and healthcare will increase progress into
health research and decrease costs of both clinical trials and daily healthcare [9]. Treating
patients and patient organisations as full partners in this process is key in moving towards
a patient-centred care model, thus building the foundation for patients to take responsibil-
ity for managing their care and overall health [10].
Evolution of patient involvement in research
Most health research would be impossible without the active involvement of patients.
Traditionally, patients have been involved “passively” as subjects/participants in re-
search, with patients and their representative organisations only rarely seen as partners
in research practices. However, the last 20 years has seen a growing interest and activity
at a local, national and international level in patient engagement and in particular a fo-
cused interest in patient and public involvement (PPI) in research, with projects in the
European Union [11, 12], Australia [13], Canada [14], UK [15] and other countries, fo-
cusing on different aspects of PPI.
Many people describe public involvement in research as research that is done with or
by the public, and not to, about, or for them [16]. Patients and the public have been “in-
volved” or “engaged” in research in a variety of different ways. For example, this includes
identifying and prioritising research topics, being part of research advisory groups and
steering groups, undertaking research projects and reporting and communicating research
findings. An obstacle to the involvement of patients is often the limited knowledge that
patients have of the technical fields of research such as biobanking and in part to the lim-
ited understanding by researchers of how patients could contribute to research (and to
biobanks). The idea of patient involvement can be difficult for researchers as it does not
adhere to the traditional “scientific method”. The experiential knowledge of patients and
the public, according to some, lacks the objectivity, verifiability, universality and
rationality of scientific knowledge [17]. However, it is now increasingly appreciated among
researchers that patients’ knowledge and experience is valuable for research and contrib-
utes to increasing the quality, relevance and appropriateness of research processes [3, 18].
PPI can also contribute to the broader democratisation of research, through participatory
forms of involvement that encourage partnership in research [19–21]. This increased ap-
preciation of early and sustained engagement and involvement of patients in research is
captured by the following quote from Kish [22]:
Actually, it’s surprising that it has taken us this long to focus on patient engagement
because the results we have thus far are nothing short of astounding. If patient
engagement were a drug, it would be the blockbuster drug of the century and
malpractice not to use it.
Leonard Kish—Principal and Co-Founder of VivaPhiKey messages
Patient involvement in biobanking activities
For most patients and patient organisations, the primary objective for their involvement
in biobanking activities is to find the cause of their disease or to improve their
Mitchell et al. Research Involvement and Engagement  (2015) 1:4 Page 5 of 17diagnosis and treatment options [23]. The degree of involvement can range from pro-
moting the existence of a biobank to governing an entire biobank. When looked at over
the last 20 years, this range of involvement has evolved through a number of important,
overlapping phases:
I: Emergence of patient-led biobanks
Although an ever-increasing number of patient organisations are establishing their own
biobank, the emergence of patient-led and patient-run biobanks began only relatively
recently. Individual patients, and representative patient organisations, many unsatisfied
with the speed of research into their respective conditions, established their own bio-
bank, primarily to enable them to provide a greater contribution and influence on re-
search in their disease area. Three case studies of patient-led biobanks in the USA
(Chordoma Foundation Biobank), Germany (Patients’ Tumor Bank of Hope (PATH)
Biobank) and Italy (Italian Biobank AHC) are provided in this article as examples in
this regard. Another example worth highlighting is the Généthon DNA and Cell Bank
driven by the French patient organisation Association Française contre les Myopathies
(AFM). AFM become active in genetic research in the 1980s to help find a cure for
neuromuscular diseases and founded the biobank in the mid-1990s [24]. The organisa-
tion has retained the decision-making power over the biobank, whilst maintaining a
tight partnership with the scientists involved and is now one of the largest banks for
genetic research in Europe [25].
Patient-led initiatives were also among the first to develop networked biobanking
activities. The European network of DNA, cell and tissue biobanks for rare diseases
(EuroBiobank) was the first pan-European network of biobanks—established in 2001
by the EURORDIS [26] and AFM patient organisations—and currently operated by
the TREAT-NMD network. This network of 16 biobanks from eight countries suc-
cessfully consulted with patient organisations in the construction of its ethical guide-
lines and consent forms. EuroBiobank continues to provide human DNA, cell and
tissue samples as a service to the scientific community conducting research on rare
diseases [27].
A further example is the patient-led “Genetic Alliance Biobank”, established in the
USA in 2003 based on the organisational strategies of PXE International, an advocacy
group set up by two parents whose children were diagnosed with the incurable condi-
tion PXE. The Genetic Alliance uses a cooperative, cost-sharing model that translates
into a tightly controlled infrastructure for patient organisations to conduct biobanking
activities. Genetic Alliance sets high standards for patient involvement in research, ex-
ceeding the requirements of applicable US federal, state and local laws, rules and regu-
lations [28].
II: Establishing the patient position on biobanks
A number of European-wide initiatives have been able to develop “representative” pa-
tient positions on biobanking. The first clear recommendation was in 2006 by the
European platform for patients’ organisations, science and industry (EPPOSI)—an EU
patient-driven partnership between patient organisations, industry and academic sci-
ence and clinicians. In the first conference to bring these different stakeholders to-
gether to discuss the future of biobanks, representatives of several patient
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effective therapies for their diseases, ii) what key role patient groups play in promoting the
need for biobanks and iii) how they contribute to raise awareness about the usefulness of
biobanks and to accelerate the collection of precious biomaterial [29].
In 2010, patient representatives of the stakeholders’ forum of Biological and Biomo-
lecular Resource Infrastructure (BBMRI) produced a “consultation document on pa-
tient perspectives” which was subsequently endorsed by a number of major pan-
European patient organisations [30]. The document describes the relevant principles
laid down in European and international instruments that cover patient participation in
networked biobanking activities. Three key principles were highlighted for the govern-
ing of active participation of patients and patient organisations in biobanking activities:
Inclusion, Engagement and Communication. Translating these key principles into prac-
tice involves:
 Inclusion of patients and patient organisations as partners in the research effort,
especially in the areas of communication, advocacy and recruitment (e.g.
information to potential donors, preparation of informed consent forms).
 When establishing sample, tissue and databanks, the experience, knowledge and
expertise of patients, families and carers should be considered.
 Listening to patients’ voices/expectations on research needs from their experience
from participating in biobanking as donors.
 Regular, general and reasonable feedback to patients regarding use, sharing and
transfer of samples.
In particular, the document recommends that patient involvement should be ex-
tended to ethical aspects such as informing Research Ethics Committees (RECs) of pa-
tients’ interests, patient rights over their donation, access to samples from research
groups out of the country, possible new use of existing samples and/or discontinuation
of the biobank.
In 2012, the EU-FP7 PatientPartner project identified a number of patients’ needs for
partnership in the context of clinical trials, including for biobanking activities. The pro-
ject consulted extensively with patient organisations through a number of different en-
gagement mechanisms and made recommendations on the role that patient
organisations have in biobanking, including a need to educate patient organisations on
how to start and structure a biobank [31].
III: Capturing patient and public perspectives and concerns
Biobanks create a number of ethical and legal issues related to research governance,
privacy, informed consent [32], control and ownership [33], withdrawal of samples
and consent [34], commercialisation [35], return of results and incidental findings
[36]. For biobanking operators, gaining a greater understanding of the perspectives
of different stakeholders, including patients and the public, can offer insight into
the nature and context of these ethical challenges and can assist in public
engagement.
The findings from a plethora of public consultations have shown that the public re-
sponse to biobanking activities is varied, diffuse and highly context-specific [37, 38]. In
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and reservations expressed by patients and the public, as participants in biobanking,
involve:
 the nature of consent when agreeing to participate
 the confidentiality of the tissue and of data being compromised
 access to the tissue and data after donation
 how their information might be used
 their access rights to results from research performed using their tissue and data
A common recommendation resulting from public and patient consultations is the
principle of transparency—that operators of biobanks should actively communicate
relevant information to patients in a clear and transparent fashion, thus striving to
build a relationship of trust with participants and the wider public [30]. Transparency
can be achieved through clear information being used at all times in order to foster ac-
ceptance of the ways a biobank is developed and used.
To secure the trust of patients and the public, more recently established
population-based biobanks [39, 40] have conducted consultation exercises aimed at
obtaining and incorporating patient and public perspectives into the design of the
biobank prior to its implementation [41]. However, these exercises have not provided
patients and the public with the opportunity for active involvement in running of the
biobank once it was established. An exception is the Mayo Clinic Biobank [42]
highlighted in the case studies in this article, which, using deliberative democracy
techniques [43], has involved patients and research participants in the policy and
decision-making of the biobank.
IV: Education and training
It is commonly accepted that in order to ensure that biobanks are developed and used
to their full potential, it is essential that both researchers and other stakeholders associ-
ated with biobanking have access to the best possible training and career development
opportunities at all stages of their professional life. Therefore, in order to facilitate ac-
tive participation of patients and patient organisations in biobanking activities, appro-
priate training in partnership with healthcare professionals and researchers is and will
be necessary.
A number of ongoing patient-led training initiatives in this area are helping to raise
awareness of the contribution that patients can make as partners in research. The Euro-
pean Patients’ Academy (EUPATI), an EU-wide, public-private partnership that is led
by the European Patients’ Forum and is funded by the Innovative Medicines Initiative
(IMI), provides in-depth training of patient advocates as well as educational material
on all aspects of medicines research and development (R&D) including key topics rele-
vant to patient involvement in biobanking (e.g. the principles of non-clinical develop-
ment, exploratory and confirmatory clinical development, informed consent processes
and regulatory affairs). EUPATI’s Expert Patient Training Courses are currently training
50 patient advocates, and its Internet Library will provide this information in the form
of web-based educational resources to the health-interested general public in seven lan-
guages in 2016 [12].
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course in the UK trains patient advocates in basic cancer biology, research terminology
and study design, and the critical evaluation of research proposals and scientific papers
[44]. The Genetic Alliance Biobank equips patients and the public with an understand-
ing of the opportunities and issues in becoming actively involved in biobanking through
running a regular “boot camp” providing in-depth training to assist patient organisa-
tions in creating and maintaining a registry and/or biobank [45].
Equipping research professionals with the understanding to start involving patients
and public as partners in biobanking and to develop practice is a distinct challenge in
this area. However, there remains a potential for this training to be provided in connec-
tion with leading universities/training sites/course providers in the field (e.g. P3G,
ISBER). In addition, possible topics for patient seminars, summer schools, and short/
long-term fellowships in the field of biobanking research could be a valuable addition
to current training programmes in biobanking [46].Case studies
Biobanks established by patients
There are many examples, predominantly from the rare disease patient community, of
patient stakeholders who have invested their own resources in the establishment of
new biobanks and biobank infrastructures. Below are three case studies which capture
the levels of involvement and the resulting value to the biobank itself.
Case study 1:Name of the
biobank
Patients’ Tumor Bank of Hope (PATH Biobank)
Date established 2002
Size Approximately 7500 patients have consented to be donors with seven sample source sites
across Germany (ongoing)
Host organisation PATH Foundation, Germany
Country or region Germany
References References 47 and 48 belowBreast cancer survivors established the PATH Biobank in 2002 as a non-profit organisa-
tion to collect human tumour and blood samples, together with patient data (and follow-
up data) at high ethical standards and under uniform SOPs. PATH [47] aims to involve
the breast cancer patients as much as possible in its work through the following strategy:
1. The current PATH board consists of three breast cancer survivors, which
according to its statutes, at least two members have to be former patients. In
addition to the representation (e.g. at conferences and towards scientific partners),
the board guides the activities and direction of PATH Biobank. As breast cancer
survivors, all board members have an inherent motivation to contribute to the
cure of this disease.
2. PATH respects the proprietary right of the breast cancer patient. The patient
donates their blood and tumour, and in return, PATH reserves one aliquot of both
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samples at any time, free of charge. This way, the breast cancer patient is directly
involved in the biobanking process and may benefit from the storage of her
biospecimens.
3. PATH patients provide their follow-up data. In a follow-up study, PATH patients
were re-contacted by telephone. More than 75 % of contacted patients provided
data about their disease course and medical treatments. The extraordinarily high re-
sponse rate reflects the patients’ trust and interest in PATH’s work [48].
4. PATH is transparent. PATH publishes the results of studies performed with
PATH samples on the PATH website (http://www.path-biobank.org). This way,
PATH patients can directly see what PATH samples have achieved. Additionally,
PATH biospecimen donors receive a yearly newsletter. The newsletter covers
topics like clinical studies, new therapeutics and progresses in research and
development. The patients’ feedback indicates that they appreciate the
newsletter. Importantly, only 31 % of all PATH patients use the internet as a
source of information highlighting the important role of biobanks like PATH in
patient information [48].
5. PATH consults patients free of charge concerning the handling of their tumour
tissue, especially regarding their right to self-determination. In a normal clinical
setting, there is no time to discuss the subsequent use of the tumour tissue. In-
formed patients demand to be included in these decisions. They have right to de-
cide what happens to their tumour. For these reasons, breast cancer patients may
call the PATH office and receive support free of charge. The PATH staff consists
of a physician and a biologist, thus allowing for competent consultancy regarding
all questions associated with the handling of the biomaterial and proprietary
rights.
6. PATH encourages breast cancer patients to become active and support PATH’s
work by volunteering their time. As a non-profit organisation, PATH is always look-
ing for volunteers. This is done via the PATH newsletter, an email-newsletter and
patient events.
Case study 2:Name of the biobank Chordoma Foundation Biobank
Date established 2012
Size 110+ samples (ongoing)
Host organisation Chordoma Foundation
Country or Region North Carolina, USA, with four partner sites/hospitals across the USA
References Reference 49 belowChordoma is a rare bone cancer that can occur anywhere along the spine. The Chor-
doma Foundation was founded in 2007 by Josh Sommer, a then 17-year-old patient,
and is a small, volunteer-run patient organisation. The Chordoma Foundation decided
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the biobank but to remain in control and act as the formal “sponsor” of the research
arising from the use of the tissue. The biobank is designed, supported and operated by
the staff and board of the foundation, with the assistance of a Scientific Advisory Board,
and third parties where appropriate (e.g. storage). The foundation operates its biobank
under an institutional review board (IRB) approved research protocol.
The patient-led biobank team works closely with hospitals to coordinate chordoma
tissue collection from patients, providing the first centralized source of chordoma sam-
ples and data to the research community. The foundation also developed a standard-
ized kit to make it easy for any hospital to provide tissue samples, thus ensuring the
quality of sample collection and preservation during transport.
As the condition is very rare, and the tissue so scarce, the foundation has made spe-
cific efforts to liaise closely with hospitals to collect any chordoma tissue remaining
from surgical procedures that is not needed for patient care. The foundation has also
set up partnership networks with hospitals that are centres of excellence for the treat-
ment of chordoma patients to routinely collect chordoma tissue. Expanding the bio-
bank network to Europe and exploring “virtual” biobank solutions (where specimens
are administered centrally but stored locally) are currently being investigated. A major
goal for the near future is to acquire more frozen samples suitable for genetic research.
Volunteers and patients are also involved in promoting the biobank to the public
through the foundation’s online (social media, website) and offline (face-to-face meet-
ings, mailings, brochures) tools and channels. Because the patient organisation is in the
driver’s seat, chordoma patients are very easily convinced about the necessity of tissue
donation. This has all been achieved with the support of chordoma patients and their
families, acting as volunteers, and a small staff (<5). The Foundation board consists of
patients or relatives of patients, in the majority. The message from the Chordoma
Foundation is that patient/volunteer-led biobanking can be performed very effectively,
even by very small organisations, and may be the only solution for some rare diseases.
Case study 3:Name of the biobank I.B.AHC—Italian Biobank for Alternating Hemiplegia of Childhood
Date established October 2004
Size 48 patients (ongoing)
Host organisation Scientific Institute IRCCS “E. Medea”
Country or region Bosisio Parini (LC)—Italy
References Reference 50 belowAlternating Hemiplegia of Childhood (AHC) is a very rare, progressive and debilitat-
ing neurological disease, characterized by an early onset. The Italian Association for Al-
ternating Hemiplegia of Childhood (AISEA) is actively involved in their Italian Biobank
AHC (I.B.AHC), an open repository by which the clinical information and the bio-
logical material of AHC patients with a validated diagnosis are collected and made us-
able for any research project on AHC [50]. The I.B.AHC Biobank and associated
clinical registry are fully integrated and have been funded and coordinated by the pa-
tient association since 2004, in association with its scientific committee.
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and a biobank of DNA samples from participating patients. AISEA defined both the
biobank and registry protocols together with its scientific committee and with the eth-
ics committee of the scientific institute hosting the biobank (MEDEA, Italy). The in-
formed consent forms for patients and the Material and Data Transfer Agreement
(MDTA) for the researchers applying for access were also defined by the patient organ-
isation in collaboration with the MEDEA Ethics Committee.
AISEA has a primary responsibility for the recruitment of AHC patients and plays a
vital role in active communication with patients, particularly about the process of sam-
ple/data collection, as well as information on the communication of individual results
obtained by the research projects that used their sample/data. According to conditions
stated in the MDTA, AISEA enters the individual results of the research projects acces-
sing I.B.AHC into the clinical registry, so that they can be seen and used by any other
future study accessing I.B.AHC. In this way, the patients, by donating their data and
samples to I.B.AHC, obtain the maximum return of their investment for the progress
of research on AHC. AISEA also communicates the individual results of the studies
accessing I.B.AHC to the patients and to their treating physicians.
The I.B.AHC was the largest case series included in an international collaborative re-
search project that in July 2012 identified mutations in the ATP1A3 gene as the major
cause for AHC. The I.B.AHC organisational and information model, in compliance with
the model developed by ENRAH, the European Network for the Research on AHC, is
now being used to create an international network of homogeneous clinical registries with
linked biobanks as a supporting infrastructure for the International Consortium for the
Research on AHC (IAHCRC). In this initiative, the AISEA together with other national
patient associations for AHC are playing an essential role in its governance, not only for
guaranteeing the sustainability of this infrastructure and the recruitment of the patients
but also for the definition of rules for sharing of the data and samples inside IAHCRC.
Patient involvement as part of biobank governance
Biobanks are increasingly incorporating patient involvement as an important part of
their governance structures. Three case studies are presented below.
Case study 4:Name of the biobank Wales Cancer Bank
Date established 2004
Size Currently 12,000 patients (ongoing)
Host organisation Cardiff University
Country or region Wales, UK
References Reference 51 belowThe Wales Cancer Bank (WCB) is funded by the Welsh Government and Cancer Re-
search Wales and is hosted by Cardiff University [51]. Patient involvement has been
key to the development of the WCB since its inception and the insight given by the lay
members complements and augments the expertise of the professionals involved in
managing and advising the project.
Mitchell et al. Research Involvement and Engagement  (2015) 1:4 Page 12 of 17A steering group was convened when the biobank was founded to ensure all relevant
stakeholders were able to input into the formation and initiation of the WCB. Of the
38 steering group members, four were “lay members” recruited either through personal
contact or via the local patient support groups and/or networks. Three lay members
were patients, and one was a caregiver for a cancer patient. These four lay members
went on to form the core of the patient and ethics committee, which drafted the ethics
application, the patient information sheet and consent form and advised on the pro-
posed patient pathways. They were instrumental in keeping the discussions grounded,
ensuring the language and content of the patient documentation was suitable and giv-
ing invaluable advice regarding the timing and method of consent.
The patient and ethics committee was later reconfigured and revitalised to become
the Lay Liaison and Ethics group (LLEG). The group expanded its lay membership fur-
ther to include a public relations expert, a fundraising expert and additional patients.
Mr. Neil Formstone, who was one of the original three patients involved in the steering
group and who remained heavily involved as a committed patient advocate until his
death in December 2012, initially chaired the new group. The Chair of the LLEG com-
mittee is a full member of the WCB Executive group, which is the central pillar of the
governance structure responsible for the operational decisions. The Executive group re-
ports to an overarching Advisory Board with a remit to oversee the progression and fu-
ture strategy of the WCB. The lay voice is, therefore, an integral part of the Executive
group and is also heard at Advisory Board meetings where the Executive group is in at-
tendance. The Chair of the Advisory Board is also currently a lay member.
The Lay Liaison and Ethics group has expanded further with three new patient mem-
bers and has concentrated on raising the profile of the biobank through their interactions
with patient groups, hospital groups and other organisations, such as Rotary. The mem-
bers regularly review the communication strategy and are the first port of call for WCB to
explore any proposed new processes. The value WCB places on the views and advice of
the members of the LLEG committee was recently demonstrated when two suggested
new procedures were first presented to the group prior to higher level discussion at the
Advisory Board. Electronic consenting and volunteer consenting were both (individually)
submitted to the group and only with their support have both schemes been progressed
further for more detailed investigation and potential implementation.
A sub-committee of members of the Lay Liaison and Ethics group has started to re-
view the lay summaries on the applications that the WCB receives for samples to en-
sure that they are understandable to a general audience. Researchers will not receive
samples until the reviewing LLEG member is satisfied that the content and structure of
the lay summary describes the proposed research in terminology suitable for a lay audi-
ence. These summaries are uploaded onto the WCB website and feature in the annual
report to publicise the projects supported by the collection.
Case study 5:Name of the biobank The Mayo Clinic Biobank
Date established 2009
Size The target goal is to obtain 50,000 biospecimens (ongoing)
Host organisation Mayo Clinic, Rochester
Country or region Minnesota, USA
References Reference 52 below
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public participants created recommendations for the design of the Mayo Clinic Biobank
[52]. The hopes and values expressed guided Mayo Clinic’s development of the bio-
bank, particularly its procedures and practices to protect the individuals donating to
the biobank. One recommendation voiced by the participants was the need for ongoing
community guidance and involvement in biobank governance. Therefore, Mayo Clinic
established a Community Advisory Board (CAB) to ensure that the voice of the com-
munity continues to be heard. The Mayo Clinic Biobank CAB is composed of approxi-
mately 20 members chosen to reflect the diversity of community interests and
backgrounds, several of whom participated in the Biobank’s deliberative community en-
gagement event. The CAB provides community input to the biobank leadership about
current and future plans for maintenance and growth. Whilst the recommendations
provided by the CAB members to the leadership are not binding, they are viewed with
considerable respect and are often incorporated into policies, actions and decisions that
leadership make. The CAB is co-chaired by a community member (elected by CAB
members) and a member of the Mayo Clinic Biomedical Ethics Program. The co-chairs
work with Biobank staff to set meeting agendas and facilitate CAB meetings. Both co-
chairs are also active voting members of the Biospecimen Trust Oversight Group and
Biobank Access Committee. A community vice chair (elected by CAB members) is also
part of CAB leadership and helps with co-chair responsibilities. In 2008, CAB members
met with Mayo Clinic Biobank staff members to assist in creating the Biobank’s in-
formed consent procedures and review recruitment materials and methods. Many of
the improvements and suggestions generated by the CAB were adopted by the Mayo
Clinic Biobank before it began operations in April 2009. Since then, the Biospecimen
Trust Oversight Group has asked the CAB to review and recommend policies and pro-
cedures on issues arising in Biobank research, such as return of research results, data
sharing with other researchers, procedures used to recruit Biobank donors and many
other topics. The CAB meets every other month to learn about, discuss and develop
recommendations to help guide the Biobank leadership.
Case study 6:Name of the biobank Nottingham Health Science Biobank
Date established January 2011
Size The aim is to consent every patient at the time of first presentation at our hospital
and those referred for surgery and treatment after diagnosis (ongoing)
Host organisation Nottingham University NHS Hospitals Trust
Country or region Nottingham, UK
References Reference 53 belowThe Nottingham Health Science Biobank (NHSB) has pioneered an innovative
model of patient-led consent which is being piloted and developed with the help of
the Biobank PPI Advisory Group, comprising volunteer patients, carers and the public
[53]. In this model, patients themselves lead the consent process for biobanking.
Many of the patient volunteers have experience of the diseases the NHSB is
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with an important stakeholder that biobanks often neglect—the patient donors of the
tissue samples.
Nottingham University Hospitals have 1500 PPI members on their database. To en-
gage the volunteers, an expression of interest was sent to 200 PPI members outlining
what the NHSB did, why it was set up and the activities that would be requested for
PPI members to become involved in. These activities included the design develop-
ment and delivery of innovative, effective and user-friendly consenting processes to
encourage improved donation activity, delivery of easy-to-understand information
for patients and the public, and provision of greater opportunities to share biobank-
related news with patients and the public via various media sources on a local, re-
gional and national level. As part of the process, a comprehensive job description
was created including the nature of the role for a person consenting, time commit-
ment, support and reporting, confidentiality, probationary period and length of
membership. A comprehensive “person specification” also outlined the essential and
desirable skills for experience, special attributes and communication skills. From this
process, 25 people who were interested in the NHSBs’ activities were identified and
invited to a face-to-face meeting. After further consultation with the PPI advocates,
nine wished to take part in the consent process for the NHSB. PPI members who
wished to take part:
 received full mandatory training and induction by the Hospital Trust
 were given an Honorary Trust contract
 had to sign a confidentiality agreement
 were required to have a Criminal Records Bureau (CRB) check and engage with the
Independent Safeguarding Authority (ISA) to carry out the Disclosure and Barring
Service (DBS)
 were provided with Hospital badges
 were given free car parking permits
 were reimbursed for travel expenses
In addition, the NHSB also produced a comprehensive consent training package
which included:
 a presentation followed by role plays
 hand-holding in the clinic for a minimum of six clinics. This aspect of the training
was tailored to the individual and no time limits were set
 shadowing and review
 direct observation and final competency sign offs
Each advocate was also provided with one-to-one training and taken through the full
life cycle of biobanking. As part of their ongoing professional development, the PPI ad-
vocates are also offered annual appraisals. NHSB have now recruited five PPI Advo-
cates, all of whom have had breast cancer or are the partners of people with a history
of breast cancer, to lead the process of consent in this specialist area. Since August
2012, the PPI advocates have been responsible for consenting in five out-patient breast
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and has led to increases in the rates of consent.
The use of PPI advocates to take consent is cost-effective and embeds the patient per-
spective at the core of the biobanking process. According to NHSB, this is the first de-
scription of a novel and broadly applicable approach to consent for biobanking. In
addition, the current PPI advocates have expressed an enthusiasm to be involved in
training of future biobank volunteers. The NHSB continues to promote PPI and patient
and public engagement (PPE) through regular group meetings, open days and speciality
targeted workshops.
Conclusions
Reflecting a “cultural revolution” in health research over the last two decades, we be-
lieve that PPI in biobanking practices and research is here to stay. PPI represents an
ideological shift within which patients can take a more central, driving role in research
that affects their health and healthcare.
This article provides examples of the variety of ways that active patient involvement
has been conducted to date. It also provides evidence to support the importance of
early and sustained engagement and involvement of patient representatives in biobanks.
As more and more biobanks are created in the future, so too will the number of pa-
tients and patient organisations that get involved in biobanking, as donors, as active
participants and collaborators in research.
To facilitate this increased role as collaborators in biobanking, appropriate training is
necessary and more information should be disseminated as to how patients can con-
cretely contribute to biobank-based research.
In-depth training and educational resources are now available, for example, through
the EUPATI’s Expert Patient Training Courses, the EUPATI Internet Library—becom-
ing available in 2016 in seven languages, as well as the Cochrane’s “Consumers for
Evidence-Based Healthcare” initiative [54]. In addition, as biobanks in general are
evolving from the stand-alone, proprietary model to more networked, harmonized
models, there is now a significant opportunity to assess the extent of patient and public
involvement across all biobanks and to include the PPI perspective in international ini-
tiatives of biobanking harmonisation like BBMRI and ISBER.Fig. 1 Potential roles, supportive infrastructures and likely outcomes of PPI in biobanking activities. Adapted
with permission from TwoCan Associates [55]
Mitchell et al. Research Involvement and Engagement  (2015) 1:4 Page 16 of 17Organising and facilitating PPI activity in biobanking takes considerable time and ef-
fort for all stakeholders involved. Therefore, for any biobank operator considering in-
volving patients in their biobanking activities, consideration of best practices, current
guidance, ethical issues and evaluation of involvement will be important. To act as ref-
erence guide in this regard, the examples of involvement outlined in this article are
summarized and illustrated in Fig. 1, with potential roles, supportive infrastructures
and likely outcomes for PPI in biobank-based research highlighted.
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